Skip to main content
SpringerLink
Log in

Life After Urological Cancer – Psychological Issues

  • Chapter
  • First Online:
Urological Oncology

  • 1625 Accesses

Abstract

About half of patients treated for urological cancer will experience some degree of psychological distress and about a quarter have some degree of depression at some time in their illness. Patients with prostate cancer have lower levels of anxiety and depression compared to some other cancers. Psychological symptoms may be overshadowed by physical symptoms. However, useful clinical screening tests include the simple question “are you feeling down, depressed or hopeless?” and questions about sleep disturbance may identify depressed patients. The diagnosis of anxiety and depression may be helped by screening tools such as the Hospital Anxiety and Depression Scale (HADS) but we have found simple analogue scales (the Emotion Thermometers) much less laborious to use and equally accurate. Fatigue is one of the most common symptoms amongst cancer patients and can be worsened by radiotherapy and the use of androgen deprivation therapy (ADT). Fatigue is associated with depression in about half of patients. Graded aerobic exercise programmes should be considered for patients suffering from fatigue rather than the classical advice of rest, which could be detrimental. Minor degrees of cognitive dysfunction particularly reduction in immediate and working memory are common in men treated with ADT and occasionally can be severe. Recognition and treatment of distress, anxiety and depression can markedly improve the quality of life in patients treated for urological cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. NCCN Clinical Practice Guidelines in Oncology: Distress Management V1 2007 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 10 Feb 2012.

  2. Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer. 2001;84:1011–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Saraceno B, Laviola F, Sternai E, et al. Consequences of mental distress recognition in general practice in Italy – a follow up study. Soc Sci Med. 1994;39:789–96.

    Article  CAS  PubMed  Google Scholar 

  4. Mulder RT. An epidemic of depression or medicalization of distress. Perspect Biol Med. 2008;51:238–50.

    Article  PubMed  Google Scholar 

  5. Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol. 2007;25:4670–81.

    Article  PubMed  Google Scholar 

  6. Shim EJ, Mehnert A, Koyama A, et al. Health related quality of life in breast cancer: cross-cultural survey of German, Japanese and South Korean patients. Breast Cancer Res Treat. 2006;99:341–50.

    Article  PubMed  Google Scholar 

  7. Faller H, Bulzebruck H, Drings P, Lang H. Coping, distress and survival amongst patients with lung cancer. Arch Gen Psychiatry. 1999;56:756–62.

    Article  CAS  PubMed  Google Scholar 

  8. Wariach P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49:123–38.

    Google Scholar 

  9. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety and adjustment disorder in oncological haematological and palliative care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74.

    Article  PubMed  Google Scholar 

  10. Salvo N, Zeng L, Zhang L, et al. Frequency of reporting and predictive factors for anxiety and depression in patients with advanced cancer. Clin Oncol. 2012;24:139–48.

    Article  CAS  Google Scholar 

  11. Hinz A, Krauss Q, Stolzenberg J-U, et al. Anxiety and depression in patients with prostate and other urogenital cancer: a longitudinal study. Urol Oncol. 2009;27:367–72.

    Article  PubMed  Google Scholar 

  12. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374:609–19.

    Article  PubMed  Google Scholar 

  13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  14. Mitchell AJ, Lord K, Symonds P. Which symptoms are indicative of DSMIV depression in cancer settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms. J Affect Disord. 2012;138:137–48.

    Google Scholar 

  15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

    Article  CAS  PubMed  Google Scholar 

  16. Mitchell AJ, Meade N, Symonds P. Diagnostic validity of the hospital anxiety and depression scale (HADS) in cancer and palliative settings: a meta-analysis. J Affect Disord. 2010;126:335–48.

    Article  PubMed  Google Scholar 

  17. Mitchell AJ, Baker-Glenn EA, Granger L, Symonds P. Can the distress thermometer be improved by additional mood domains? Part 1. Initial validation of the emotion thermometer tool. Psychooncology. 2010;19:125–33.

    Article  PubMed  Google Scholar 

  18. Mitchell AJ, Baker-Glenn EA, Park B, Granger L, Symonds P. Can the distress thermometer be improved by additional mood domains? Part II. What is the optimal combination of emotion thermometers. Psychooncology. 2010;19:134–40.

    Article  PubMed  Google Scholar 

  19. Storey DJ, Waters RA, Hibberd CJ, et al. Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Center symptom study. Ann Oncol. 2007;18:1861–9.

    Article  CAS  PubMed  Google Scholar 

  20. Stone P, Richards M, A’Hearn R, et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000;11:561–7.

    Article  CAS  PubMed  Google Scholar 

  21. Hickok JT, Roscoe JA, Morrow GR, et al. Frequency, severity clinical course and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104:1772–8.

    Article  PubMed  Google Scholar 

  22. Zeng L, Koo K, Zhang L, et al. Fatigue in advanced cancer patients attending an outpatient palliative radiotherapy clinic as screened by the Edmonton symptom assessment system. Support Care Cancer. 2011. doi:10.1007/s00520-11-1179-8.

    Google Scholar 

  23. Storey DJ, McLaren DB, Atkinson MA, et al. Clinically relevant fatigue in recurrence-free prostate cancer survivors. Ann Oncol. 2012;23(1):65–72.

    Article  CAS  PubMed  Google Scholar 

  24. Windsor PM, Nichol KF, Potter J. A randomised controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localised prostate cancer. Cancer. 2001;101:550–7.

    Article  Google Scholar 

  25. Saini A, Berruti A, Cracco C, et al. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. Urol Oncol. 2013;31:352–8.

    Article  PubMed  Google Scholar 

  26. Sherwin BB. Steroid hormones and cognitive functioning in aging men: a mini-review. J Mol Neurosci. 2003;20:385–97.

    Article  CAS  PubMed  Google Scholar 

  27. Edinger KL, Frye CA. Testosterone’s analgesic, anxiolytic and cognitive – enhancing effects may be due in part to actions of its 5 alpha-reducing metabolites in the hippocampus. Behav Neurosci. 2004;118:1352–64.

    Article  CAS  PubMed  Google Scholar 

  28. Frye CA, Edinger KL, Seliga AM, Wawrzycki JM. 5 alpha-reducing androgens may have actions in the hippocampus to enhance cognitive performance of male rats. Psychoneuroendocrinology. 2004;29:1019–27.

    Article  CAS  PubMed  Google Scholar 

  29. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer. Cancer. 2008;113:1097–106.

    Article  CAS  PubMed  Google Scholar 

  30. Carlson LE, Waller A, Mitchell AJ. Evidence-based screening for distress and unmet needs. J Clin Oncol. 2012;30:1160–77.

    Google Scholar 

  31. Schofield P, Gough K, Lotfi-Jam K, Aranda S. Validation of the Supportive Care Needs Survey-short form 34 with a simplified response format in men with prostate cancer. Psychooncology. 2012;21:1107–12. doi:10.1002/pon.2016.

    Article  PubMed  Google Scholar 

  32. Boberg EW, Gustafson DH, Hawkins RP, et al. Assessing the unmet information, support and care delivery needs of men with prostate cancer. Patient Educ Couns. 2003;29:233–42.

    Article  Google Scholar 

  33. Duke JM, Treloar CJ, Byles JE. Evaluation of an instrument to assess the needs of men diagnosed with prostate carcinoma: an assessment of the validity and reliability of a self-administered questionnaire developed to measure the needs experienced by men diagnosed with prostate carcinoma. Cancer. 2003;97:993–1001.

    Article  PubMed  Google Scholar 

  34. Duke JM, Treloar CJ, Byles JE. Evaluation of a revised instrument to assess the needs of men diagnosed with prostate cancer. Support Care Cancer. 2005;13:895–903.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Studies and Molecular Medicine, University of Leicester, Level 2, Osborne Building, Leicester Royal Infirmary, Leicester, LEI 5WW, UK

    Paul Symonds MD, FRCP & Alex J. Mitchell MBBS, BMedSci, MSc

  2. Department of Palliative Care, University Hospital of Leicester NHS Trust, Leicester, UK

    Karen W. E. Lord BA, MSc

Authors
  1. Paul Symonds MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen W. E. Lord BA, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alex J. Mitchell MBBS, BMedSci, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Symonds MD, FRCP .

Editor information

Editors and Affiliations

  1. Department of Urology, Homerton University Hospital & Formerly St. Bartholomew's Hospital, London, United Kingdom

    Vinod H. Nargund

  2. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Derek Raghavan

  3. Radiation Oncology, Cedars Sinai Cancer Center, Los Angeles, California, USA

    Howard M. Sandler

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Symonds, P., Lord, K.W.E., Mitchell, A.J. (2015). Life After Urological Cancer – Psychological Issues. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-482-1_16

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-481-4

  • Online ISBN: 978-0-85729-482-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation